PRESS RELEASE
For Immediate Release

NADMED secures U.S. patent for the extraction method behind its NAD assays

The grant marks an important milestone for the University of Helsinki spin-out and recognizes the scientific innovation of its founders

HELSINKI, Finland, November 2026: NADMED, a University of Helsinki spin-out specializing in the measurement of NAD and glutathione redox metabolites, has announced that the United States Patent and Trademark Office (USPTO) has granted the company its first U.S. patent. The grant is an important milestone for NADMED. It protects the proprietary method at the core of the company's technology and further differentiates NADMED in the emerging field of NAD measurement.

The U.S. Patent was issued on 10 November 2026 and covers NADMED's method for extracting NAD metabolites, and glutathione with them, from whole blood, the foundation of the company's assays. The grant follows examination by the USPTO and recognizes the novelty of the method.

The patent names Liliya Euro, PhD, NADMED's Co-founder and Chief Scientific Officer, and Professor Anu Wartiovaara of the University of Helsinki, NADMED's Co-founder and Chair of the Board, as inventors. It recognizes their scientific work at the University of Helsinki, on which NADMED was founded.

"This is an important milestone for NADMED," said James Lee, CEO of NADMED. *"The patent protects the method at the core of our technology, and recognition by the USPTO reinforces what makes our approach to measuring NAD unique. NAD measurement is an emerging category, and protected technology of this kind is a lasting asset for the company. It strengthens our position at the front of that category and gives our laboratory and pharmaceutical partners added confidence in the technology they rely on."*

"This patent is the result of more than six years of hard work since the first application was filed in 2020," said Jana Buzkova, PhD, Co-founder, COO and Head of Market Expansion at NADMED, speaking on behalf of the company's founders. *"It reinforces what makes the method Liliya Euro and Anu Wartiovaara invented unique. It is recognition for them as inventors, for the founders, and for everyone on the NADMED team who has helped turn that invention into a company."*

NADMED now has U.S. patent protection for its extraction method and, in the European Union, a CE-marked NAD+ and NADH blood kit. Together they support NADMED's long-term strategy of growing its scientific and commercial presence internationally.

END

Notes to editors

About NADMED
NADMED is a University of Helsinki spin-out based in Helsinki, Finland. It develops and manufactures assays for the quantitative measurement of NAD+, NADH, NADP+ and NADPH in human whole blood, used by laboratories in Europe and the U.S. Glutathione (GSH and GSSG) is measured in NADMED's Helsinki laboratory.

In the European Union, the Q-NADMED Blood NAD+ and NADH Assay Kit is CE-marked under the In Vitro Diagnostic Directive (98/79/EC). All other NADMED kits are for research use only. NADMED's assay kits are labeled for research use only in the United States and are not cleared or approved by the FDA.

www.nadmed.com

Media contact
James Godfrey, Kode: hello@agencykode.com